Castleark Management’s OptimizeRx OPRX Stock Holding History

Castleark Management’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-113,822	Closed	-$7.07M	–	352
2021 Q4	$7.07M	Sell	113,822 -44,900	-28%	-$3.4M	0.26%	95
2021 Q3	$13.6M	Buy	158,722 +4,790	+3%	+$301K	0.52%	45
2021 Q2	$9.53M	Buy	153,932 +65,077	+73%	+$3.31M	0.32%	85
2021 Q1	$4.33M	Buy	+88,855	New	+$4.29M	0.16%	145

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Castleark Management's OPRX Position: Q1 2022 in Review

Castleark Management sold out of OptimizeRx (OPRX) in Q1 2022, closing a stake of 113,822 shares — an estimated $7.07M sold.

Castleark Management first reported a position in OPRX in Q1 2021 and held it in 4 quarters. The position peaked at $13.6M in Q3 2021. 153 funds tracked by Wall St. Rank hold OPRX as of Q1 2022.

Castleark Management reported no remaining OptimizeRx position as of Q1 2022 after selling out during the quarter.
Castleark Management sold 113,822 OptimizeRx shares in Q1 2022, an estimated $7.07M.
Castleark Management first reported a position in OptimizeRx in Q1 2021 and held it in 4 quarters.
Castleark Management's OptimizeRx position peaked at $13.6M in Q3 2021.
153 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2022.

Based on Castleark Management's 13F filing for Q1 2022, filed 16 May 2022.